The drug policy of Portugal was put in place in 2001, and was legally effective from July 2001. The new law maintained the status of illegality for using or possessing any drug for personal use without authorization. However, the offense was changed from a criminal one, with prison a possible punishment, to an administrative one if the amount possessed was no more than a ten-day supply of that substance.
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
The Achilles tendon is the connection between the heel and the most powerful muscle group in the body. This has long been known as a site which is prone to disabling injury. Forces up to 12 times body weight (9kN) may arise during sprinting.
The tendon can swell and may cause pain. This condition is common in athletes, runners and patients who have calf tightness. Achilles tendinosis may occur in the middle of the tendon. This is known as midsubstance Achilles tendinosis. It may also occur at the point where the tendon connects to the heel bone.
ACHILLES TENDINOSIS & Cannabis studies completed
related cannabis studies
also see PAIN and cannabis
Increased Expression of Cannabinoid CB(1) Receptors in Achilles Tendinosis
The endogenous cannabinoid system is involved in the control of pain. However, little is known as to the integrity of the cannabinoid system in human pain syndromes. Here we investigate the expression of the cannabinoid receptor 1 (CB1) in human Achilles tendons from healthy volunteers and from patients with Achilles tendinosis.
Cannabinoid CB1 receptor immunoreactivity (CB1IR) was evaluated in formalin-fixed biopsies from individuals suffering from painful Achilles tendinosis in comparison with healthy human Achilles tendons.
CB1IR was seen as a granular pattern in the tenocytes. CB1IR was also observed in the blood vessel wall and in the perineurium of the nerve. Quantification of the immunoreactivity in tenocytes showed an increase of CB1 receptor expression in tendinosis tissue compared to control tissue.
Expression of cannabinoid receptor 1 is increased in human Achilles tendinosis suggesting that the cannabinoid system may be dysregulated in this disorder.
It has been known for many years that cannabinoids are effective for the relief of a variety of types of pain, and activation of cannabinoid (CB) receptors by compounds such as nabilone have been shown to have clinical utility in a variety of pain states, including cancer pain, neuropathic pain, and fibromyalgia. Data from studies on experimental animals indicate that the antinociceptive effects of cannabinoids are not only centrally mediated, but that spinal and peripheral CB receptors are involved.
The antinociceptive effects of exogenous CB receptor agonists raise the possibility that the endocannabinoid system is dysfunctional in pain states. There is evidence of this in animal models of pain, but little is known about the situation in human pain. To our knowledge, the only data so far reported are findings of an increased plasma concentration of the endocannabinoid anandamide in patients with complex regional pain syndrome compared to age- and sex-matched controls, a negative correlation between CB1 receptor expression in pancreatic nerves and strong pain symptoms in patients with pancreatic cancer, and a positive correlation of suburothelial CB1-immunoreactive nerve fibers with the pain score in painful bladder syndrome. There is thus a need for more data on the status of the endocannabinoid system in human pain states.
The Achilles tendon is the strongest tendon in the body and the understanding of pain in this tendon is of utmost importance. When there is chronic pain and impaired function in the Achilles tendon, the condition is referred to as tendinopathy. Clinically, the tendon thickens and becomes tender. Biopsies show changes in the appearance of the tenocytes, hypercellularity and neovascularization and eventually degenerative features. When there are structural changes, the condition is commonly called tendinosis.
Achilles tendinosis most often occurs in the mid-portion of the tendon. Imaging with ultrasonography or magnetic resonance imaging (MRI) can be used to verify tendon abnormalities in the painful area. The pain in chronic Achilles tendinosis remains an enigma. However, injections and mini-surgery to areas of neovascularization outside the tendon have been shown to reduce the pain seen in chronic Achilles tendinosis. Although several molecular candidates have been identified and proposed as mediators of the pain in Achilles tendinosis, information on the cannabinoid system is lacking. In consequence, we have investigated the expression of CB1 receptors in human Achilles tendons and whether there is a change in expression in Achilles tendinosis.
The Committee of Ethics at the Faculty of Medicine, Umeå University and the Regional Ethical Review Board in Umeå approved the project (04-157 M). Participants gave verbal consent to participate in the research after reading an explanatory statement and receiving a verbal summary of the project. The Review Board approved the verbal consent procedure. When approval from patients had been obtained, specimens were collected and taken care of for the research and documentation was made. This form of approval and documentation is in accordance with paragraph 16 and 17 of the Ethical review act in Sweden. All procedures followed the principles of the Declaration of Helsinki.
This investigation included tissue samples from 24 individuals: 11 males and 13 females (mean age: 48 years, range 21–70 years; male mean age: 44 years, range 28–70 years; female mean age: 52 years, range 21–68 years). The samples were from a group of patients suffering from Achilles tendinosis and from healthy controls. The Achilles tendinosis group (n=17) were suffering from chronic painful mid-portion Achilles tendinosis. This group consisted of 8 males and 9 females (mean age: 51, range 28–70 years; male mean age: 45 years, range 28–70; female mean age: 57 years, range 47–68 years). Tendinosis was verified by ultrasonography. The control group consisted of individuals (n=7) with no history of pain symptoms from their Achilles tendons (mean age: 41 years, range 21–47 years; 3 males, mean age 41 years, range 39–46 years; 4 females, mean age: 41, range 21–47 years). Ultrasonography showed normal tendons. All patients were otherwise healthy and non-smokers.
Sampling, fixation and sectioning
In the tendinosis group, biopsies were taken during surgical treatment. Under local anaesthesia (4–5 ml pilocaine hydrochloride, 10 mg/ml; AstraZeneca, Södertälje, Sweden), tendon tissue (macroscopically abnormal) was taken from the ventral part of the Achilles tendon through a longitudinal incision lateral to the tendon mid-portion. The biopsies contained tendon tissue proper, and to varying degrees, outer parts of the tendon (paratendinous connective tissue). The tissue samples were approximately 2 mm wide and 1–5 mm long and were taken from different depths of the tendon. From the control group, samples of the same size were collected from the dorsal part of the tendon using a longitudinal plain incision under local anaesthesia. The dorsal part of the tendon was chosen for ethical and practical reasons.
Directly after the surgical procedures, the samples were fixed overnight at 4°C in a solution of 4% formaldehyde in 0.1 M phosphate buffer, pH 7.0, followed by thorough washing in Tyrode's solution containing 10% sucrose, at 4°C overnight. The samples were then mounted on thin cardboard in OCT embedding medium (Miles Laboratories, Naperville, IL,USA) and frozen at −80°C until sectioning.
For the immunofluorescence and morphologic investigations, series of 7 µm thick sections from both groups of samples were cut using a cryostat (Leica Microsystem CM3050S, Heidelberg, Germany). The sections were mounted on slides, pre-coated with crome-alun gelatine, and the sections were then dried and thereafter processed for immunohistochemistry. Staining with hematoxylin-eosin was carried out to delineate tissue morphology. Reference tissues (human colonic and rat dorsal root ganglion tissue), available at the laboratory, were examined in parallel. They had been fixed and further processed in the same way as the tendon samples.
Sections were initially treated with acid potassium permanganate for 2 min to enhance the visualization of specific immunofluorescence reaction sites. The sections were then rinsed in 0.01 M phosphate-buffered saline (PBS) pH 7.4 containing 0.1% sodium azide as preservative, for 3×5 min. After these procedures, incubation for 20 min in a 1% solution of detergent Triton X-100 (Kebo Lab, Stockholm, Sweden) in 0.01 M PBS, and rinsing for 3×5 min in PBS were performed. The sections were then incubated in 5% normal swine serum in PBS supplemented with 0.1% bovine serum albumin (BSA) for 15 min in a humid environment in room temperature. Thereafter followed incubation with the primary antibody, diluted in PBS with BSA. The incubation was performed in a humid environment and proceeded for 60 min at 37°C. The sections were then washed in PBS for 3×5 min prior to another incubation in normal swine serum for 15 min in a humid environment in room temperature, followed by incubation with the secondary antibody. This antibody corresponded to tetramethylrhodamine isothiocyanate (TRITC)- conjugated swine antirabbit igG (DakoCytomation, Glostrup, Denmark). The secondary antibody was diluted in PBS with BSA (140). Incubation proceeded for 30 min at 37°C in a humid environment. A Zeiss Axioskop II microscope equipped with an Olympus DP70 digital camera was used for examination of the sections.
For semiquantitative determination of the intensity of CB1 receptor immunoreactivity in the control and Achilles tendinosis tendons, two of the researchers (EB, SF), who were blinded to the clinical data for the patients, independently scored the CB1 expression in the sections under the fluorescence microscope. The tenocytes were scored for immunoreactive intensity (0–3 where 0 is absent and 3 is high), and the average value was taken. This method of scoring has previously been used in other published studies by co-author Forsgren, including studies using the immunofluorescence technique on tendon tissue. For the CB1 receptor immunoreactivity scores returned by the two investigators, an intraclass coefficient analysis using a two-way mixed effects model for the 24 scores gave a Cronbach's alpha reliability coefficient of 0.79, suggesting that the inter-rater reliability is acceptable.
Antibodies and control stainings
The antibodies used were against CB1 and PGP9.5. Both are rabbit antibodies. The CB1 antibody (rabbit polyclonal; ab23703; Abcam, Cambridge, UK) had been raised against the C-terminal amino acid 461–472 of human CB1. Concentrations used were 120–1100. For the experiments comparing immunoreactivity for controls and tendinosis patients, a dilution of 150 was used. The antibody to PGP9.5 (rabbit polyclonal; code 7863-0504; Biogenesis, Poole, UK), was used at a dilution of 1100, and had been raised against native brain PGP9.5.
For control purposes, sections were processed with PBS/BSA instead of primary antibodies. To confirm further the specificity, the primary CB1 antibody was pre-absorbed overnight at 4°C with its immunogenic peptide (20–100 µg/ml; ab50542; Abcam, Cambridge, UK) prior to incubation on the sections. The PGP9.5 antibody has been used in numerous studies in the laboratory and in numerous studies by others for the purpose of demarcating nerve fibres.
The two-tailed Mann-Whitney test was undertaken using the Statistical package built into the GraphPad Prism 5 computer programme for the Macintosh (GraphPad Software Inc., San Diego, CA, USA). The intraclass coefficient analysis was conducted using IBM SPSS Statistics 19 for the Macintosh (IBM Inc., Somers, NY, USA).
CB1 receptor immunoreactivity (CB1IR) in the normal Achilles tendon and in reference tissue
Figure 1 shows the CB1IR for normal Achilles tendons, in which the tendon cells (tenocytes) show the characteristic elongated appearance and, for comparative purposes, that for human colon and the rat dorsal root ganglion. For all three cases, CB1IR was seen. For the tendons, CB1IR was observed for the tenocytes (Fig. 1A) and in blood vessel walls (not shown). The reactions in the tenocytes showed a punctuate appearance along the length of the cells (Fig. 1A). Preabsorption with the corresponding peptide eliminated the immunostainings (Fig. 1B), as did control stainings when the primary antibody was omitted (data not shown). As positive controls, CB1IR was investigated in the human colon and the dorsal root ganglia. For the human colon, distinct specific reactions were seen for cells of the mucosa and submucosa and in cells in the epithelial layer (Fig. 1C), in agreement with the literature. Distinct specific reactions were also seen for neuronal perikarya of the dorsal root ganglion. The reactions occurred as granular intracellular reactions (Fig. 1E). The presence of intracellular CB1IR can also be seen in the literature. For both human colon and the rat dorsal root ganglia, preabsorption with the corresponding peptide eliminated the immunostainings (Fig. 1D and F).
CB1IR in Achilles tendinosis
The CB1IR pattern in tenocytes of samples obtained from patients with Achilles tendinosis is shown in low magnification in (Fig. 2A–B), where Fig. 2B shows that preincubation with the antigen prevents all the immunoreactive staining. At a higher magnification, a granular pattern of immunoreactivity was seen for the tenocytes. That was especially the situation for rounded/swollen tenocytes and tenocytes with a wavy appearance. These abnormally-formed tenocytes are a characteristic of Achilles tendinosis. The tenocyte reactions appeared overall to be the strongest in the tendinosis specimens.
CB1IR in blood vessel walls and nerve structures
CB1IR was also observed in blood vessel walls and in the perineurium of nerves in the samples, especially in the tendinosis samples. For the blood vessel walls (confirmed by htx-eosin staining Fig. 3A), CB1IR was in the form of fine pointed reactions (Fig. 3B). They were seen for small vessels but not for large vessels. Preabsorption with the immunising peptide confirmed specificity of the antibody (data not shown).
Nerve fascicles were demarcated via showing a distinct PGP9.5 immunoreaction (Fig. 3C). CB1IR was detected in the perineurium of the nerve fascicles. No such reactions were, on the other hand, detected within the interior of the nerve fascicles (Fig. 3D). The nerve related immunoreactions were abolished following preabsorption with the antigen peptide (data not shown).
Semiquantitative comparison of tenocyte CB1IR in controls and patients with Achilles tendinosis
A semiquantitative analysis of the reaction intensities for the tenocytes was performed. CB1 was scored in tenocytes from a total of 24 patients either suffering from chronic Achilles tendinosis or having clinically pain-free Achilles tendons. Difference in CB1 expression between groups was statistically significant (p<0.05, Mann-Whitney U test) (Fig. 4). It should be noted that the control patient with the highest CB1IR was presumably asymptomatic at the time of biopsy, but that the tendon showed pathology consistent with Achilles tendinopathy, thus questioning whether this sample is a true control. Exclusion of this sample from the data set increased the level of significance to p<0.005.
In this study we demonstrate, for the first time, that CB1IR is detectable within the tenocytes of the human Achilles tendon. Immunoreactions were also seen in the walls of small blood vessels walls and in the perineurium of nerves. On the other hand, whilst CB1IR was detectable in the neuronal perikarya of the rat spinal ganglion, CB1IR was not detectable in the nerves of tendon tissue.
The antibody used for these studies, raised against the C-terminal amino acid 461–472 sequence of human CB1, has been found previously to produce the appropriate staining in brain samples, but not to stain samples from CB1 knockout mice. The antibody has been used, by us and others, to investigate CB1 receptor expression pattern in human bladder and fallopian tube, and in colorectal and prostate cancer biopsies. We noted that immunoreactivity was present for non-neuronal cells and that it was not limited to the cell plasma membranes, but that intracellular reactions were also seen. Similarly we noted in the present study that the CB1IR was detectable intracellularly in the neuronal cell perikarya and in the cells of the mucosa/submucosa and the epithelial cells of the colon. Although at first sight this may seem strange for a G-protein coupled receptor, it is known that the majority of the endogenous CB1 receptors do not reach the cell surface, and several authors have reported the presence of intracellularly located CB1 receptors in immunohistochemical and western blot experiments. Furthermore, there is evidence in neuroblastoma cells that at least some of the intracellular CB1 receptors are functionally active and couple to the extracellular signal-regulated kinase-signalling pathway . A recent study shows that anandamide, an endogenous CB1 receptor agonist, can activate intracellular CB1 receptors and provide evidence that these are functional.
The function of the CB1 receptors in the tenocytes can at present only be a matter of speculation, but the present data add to the literature indicating that these cells are not simply inert cells but express receptors for a variety of signalling molecules that presumably affect their function. Interestingly, tenocytes in the human Achilles tendon have been found to show expression of transporters or enzymes favouring that these cells can produce nerve signal signal substances, such as acetylcholine, glutamate and catecholamines. They were also found to show expression of mRNA for substance P. They show in addition expression of receptors for neurotransmitters. These features were clearly obvious in tendinosis tendons and most clearly so for tenocytes showing abnormal appearances, whilst such features were very vague or not detected at all in normally appearing tenocytes. This means that tenocytes can develop “neuronal-like” characteristics in terms of expressions of nerve signal substances and expressions of receptors for these. It is also a well-known fact that there are no nerve fibres within the Achilles tendon tissue as such, the existing innervations being present in the outer part of the tendon (the peritendinous tissue) and to a very small extent in the connective tissue septa. These findings may suggest that biochemical mediators, such as nerve signal substances, produced in the tendon tissue, can be involved in the aetiology and pathogenesis of chronic tendon pain in tendinosis. A “biochemical model” of this type, involving other locally produced signal substances, has also previously been considered. This means that the pain is not only structural in origin. To what extent such a model is related to what we see here, i.e. an up-regulation of CB1IR for tenocytes in tendinosis tendons, the CB1 immunoreactions being especially obvious for tenocytes with an abnormal morphology, remains to be further explained. In any case, our observations show that the cannabinoid receptor system in the Achilles tendon is mainly related to the tendon cells and not being confined to the nerve fibres.
In the present study, the robust and reliable semiquantitative determination method used, also found that there was a higher CB1 receptor expression level in the tenocytes of patients with Achilles tendinosis than in the control group, suggesting that the cannabinoid system may be dysregulated in this disorder. It is possible that the increased expression may be an adaptive consequence to a loss of local endocannabinoid signalling, and it would clearly be of interest to investigate local endocannabinoid levels in microdialysis studies from this patient group.
An alternative explanation is that the increased CB1 receptor expression is due to changes in its cellular regulation produced by the local environment in the disorder. There is evidence in the literature that inflammatory processes can affect expression of CB1 receptors in some cases, but not others: Izzo et al. for example demonstrated that croton oil-induced intestinal inflammation resulted in a three-fold increase in CB1 receptor expression in the jejunum. In contrast, cystitis produced by intravesical administration of acrolein did not affect bladder CB1 investigation at the time points chosen. CB1 and CB2 receptors can be regulated by both pro- and anti-inflammatory cytokines, and a good example of this is the ability of interleukin-4 (IL-4) to increase CB1 receptor expression in lymphocytes by a Stat-6 mediated pathway. Tenocytes in primary culture express interleukin-4 (IL-4) receptors. However, inflammation presumably occurs only at the beginning of tendinosis, and there are no signs of inflammation at the time when the biopsy samples used here were taken, so that if the increased expression found in the present study emanates from the early inflammation, it would have to be a very long-lasting effect, or due to the residual presence of a factor long after resolution of the inflammation. This does not, of course, rule out the possibility that other factors, i.e. not associated with inflammation, are involved in the regulation of CB1 receptor expression in the tendons. Experiments in both patient tissue and animal models of Achilles tendinopathy are clearly needed to explore further the mechanisms behind the increased CB1 receptor expression in Achilles tendinosis.
In conclusion, the present study has demonstrated the expression of CB1 receptors in Achilles tenocytes, thereby adding to the growing list of non-neuronal cell types that express these receptors, and that their expression is increased in tendinosis. These data underline the need for further studies on endocannabinoid signalling in human pain conditions.
The authors are grateful to Ulla Hedlund for expert technical assistance.
Competing Interests: The authors have declared that no competing interests exist.
Funding: The authors thank the Swedish Science Council (Grant no. 12158, medicine, to C.J. Fowler); the Research Funds of the Medical Faculty, Umeå University (to C.J. Fowler); the Faculty of Medicine at Umeå University, the Swedish National Centre for Research in Sports and the J.C. Kempe and Seth M. Kempe Memorial Foundations, Örnsköldsvik for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Access eBook Library
Newest Website Members
If you have a website and link to us you can earn money through our affiliate program.
Our current commission rate is 15% and is paid in Canadian dollars.
Payments to partners are made during the last week of the month.
easy, all you need to do is sign up below and download the banners. By
signing up you will get a custom code that will allow us to track your
referrals. Our system tracks everything for you.
We love Partners. Sign up orif you need help. We are here for YOU.
Telephone support is provided if you need help setting up. Just message us, we’re happy to help.
Click to Search Videos
Who's Looking Now...
Endocannabinoid Health Science
- ACEA/ ARACHIDONYL/ CHLOROETHYLAMIDE a synthetic, CB1 agonist
- ACHILLES TENDINITIS
- ADDICTION (Physical)
- ADULTERANTS see SAFETY
- AIDS see HIV
- ALLERGIES TO CANNABIS
- ALS (
- AM 1346 a synthetic cannabinoid
- ANECDOTAL (personal stories)
- ANOREXIA see
- APPETITE STIMULANT
- ARCACHIDONYL-2'-CHLOROETHYLAMIDE (ACEA) a synthetic cannabinoid
- ARTERIES see HEART DISEASE
- ATTENTION DEFICIT DISORDER
- ATHEROSCLEROSIS (hardening of the arteries)
- (type of eczema)
- BETA-CARYOPHYLENE (BCP)
- BIPOLAR DISORDER
- BLOOD (Drug testing)
- BLOOD PRESSURE
- BONES see OSTEOPOROSIS
- BRAIN CELLS see NEURONS
- BRAIN (physical effects)
- BRAIN CANCER (Glioma/Brain/Head)
- BREAST CANCER
- BREATH STRIPS (also see Methods of use)
- BUGS (Plant care)
- CANCER (Breast)
- CANCER (Cervical)
- CANCER (Corolrectal)
- CANCER (Glioma/Brain/Head)
- CANCER (Leukemia)
- CANCER (Lung)
- CANCER (Lymphoma)
- CANCER (Melanoma)
- CANCER (Oral)
- CANCER (Pancreatic)
- CANCER (Prostate)
- CANCER (Risk, cannabis vs tobacco)
- CANCER (Skin)
- CANCER (Testicular)
- CANCER (Thyroid)
- CANCER (Various unnamed)
- CANNABIDIOL (CBD) annabinoid
- CANNADOR a plant extract in pill form
- CARDIOVASCULAR see HEART DISEASE
- CESAMET see NABILONE a synthetic cannabinoid
- CERVICAL (Cancer)
- CHEMICAL COMPOSITION
- CHILDREN (Young adults)
- CHRONIC CYSTITIS
- CLONING (Plant Care)
- COGNITIVE EFFECTS (IQ & memory)
- COLITIS see CROHNS
- CONTAMINANTS see SAFETY
- (Lung function)
- CP 7497 a synthetic cannabinoid
- CROHN'S (Irritable bowel syndrome (IBS) & (Ulcerative colitis)
- CRUETZFELDT (JACOB DISEASE) see MAD COW DISEASE
- CT-3 a synthetic cannabinoid
- CURING (Curing a cannabis crop properly)
- DELTA 9 (Tetrahydrocannabinol) (THC) annabinoid
YOUR GROW ROOM
- DISSMINATED SCLEROSIS (Multiple Sclerosis) (MS)
- (Sickle cell disease) (SCA) see
- DRIVING AND CANNABIS
- DRONABINOL a synthetic cannabinoid also see MARINOL a synthetic cannabinoid
- DRUG INTERACTIONS see INTERACTIONS WITH OTHER DRUGS
- DRUG TESTING
- DRUG TESTING (Blood)
- DRUG TESTING (Hair)
- DRUG TESTING (Oral)
- DRUG TESTING (Other)
- DRUG TESTING (Urrine)
- DYSTONIA (a neurological movement disorder)
- (Multiple Sclerosis) (MS) (inflammation of the brain and spinal cord)
- EDIBLES (also see Method of use)
SYSTEM (ECS) (Video)
- ERECTILE DYSFUNCTION
- FAMILIAL MEDITERRANEAN FEVER)
- FOTHERGILL'S DISEASE see TIC DOULOURREUX
- GATEWAY THEORY
- GLIOMA (Cancer)
- GLAUCOMA (Vision)
- GYNECOLOGY AND OBSTETRICS
- HAIR (Drug testing)
- HASH (Making)
- HEADACHE see MIGRAINE HEADACHE
- HEART DISEASE (Cardiovasular)
- HISTORICAL STUDIES
- HIV (AIDS)
- HOW CANNABIS WORKS (Video)
- HU-210 a synthetic cannabinoid
- HU-308 a synthetic cannabinoid
- HUNTINGTON'S DISEASE
- IDIOPATHIC INTRACRANIAL HYPERTENSION
- INTERACTIONS WITH OTHER DRUGS
- IQ (Memory & cognitive effects)
- IRRITABLE BOWEL SYNDROME (IBS) see CROHN'S
- ISAACS'S SYNDROME (Acquired neuromyotonia)
- JACOB DISEASE ( see MAD COW
- JWH-015 a synthetic cannabinoid
- a synthetic cannabinoid
- JWH-073 a synthetic cannabinoid
- LEISHMANIASIS (Caused by protozoan parasites)
- LEUKEMIA (Cancer)
- LIVER (Non hepatitis)
- LONG TERM USE EFFECTS
- LUNG (Cancer)
- LUNG FUNCTION see COPD
- LYMPHOMA (Cancer)
- MAD COW (Cruetzfeldt or Jacob disease)
MARINOL a synthetic cannabinoid
- MEIGE'S SYNDROME (Type of dystonia)
- MELANOMA (cancer)
- MEMORY (IQ or Cognitive)
- MENTAL DISORDERS see SCHIZOPHRENIA
- MENOPAUSE see AGING
- METHANANANDAMIDE (AM 356) (an Anandamide analog) a synthetic cannabinoid
- METHODS OF USE (Breath
- METHODS OF USE (Edibles)
- METHODS OF USE (Smoking)
- METHODS OF USE (Tinctures)
- METHODS OF USE (Topical Ointments)
- METHODS OF USE (Vaporizers)
- MIGRAINE HEADACHE
- MORNING SICKNESS
- MORTALITY RATES
- METHICILLIN RESISTANT STAPHYLOCOCCUS (MRSA) (a bacterium infection)
- MULTIPLE SCLEROSIS (MS)
- MUSCULAR DYSTROPHY (MD)
- NABILONE a synthetic cannabinoid
- NAIL-PATELLA SYNDROME (NPS)
- NEUROPATHIC PAIN
- (Refers to the relative preservation)
- NUTRITIONAL INFORMATION (Hemp seed)
- OBSESSIVE COMPULSIVE DISORDER
- OBESITY AND THE ENDOCANNABINOID SYSTEM (ECS) (Video)
- ORAL (cancer)
- ORAL (Drug
- ORGAN TRANSPLANTS
- OSTEOPOROSIS (Bones)
- PAINFUL BLADDER SYNDROME (PBS) see
- PARKINSON'S DISEASE
- POST TRAUMATIC STRESS DISORDER (PTSD)
- PRENATAL EXPOSURE
- TIC DOULOURREUX
- QUITTING OTHER DRUGS
- RADIATION SICKNESS
- RISK (Cancer - cannabis vs tobacco)
- R(+) - METHANANANDAMIDE (AM 356) (an Anandamide analog) a synthetic cannabinoid
is safe medicine)
- SAFETY (Adulterants & contaminants)
- SCHIZOPHRENIA (Mental disorders)
- SEEDS (Supply) also see GERMANATION. CLONING
- SICKLE CELL DISEASE (SCA) or (Drepanocytosis) (a hereditary blood disorder)
- SKIN CANCER
- SLEEP MODULATION
- SMOKED CANNABIS AS A MEDICATION also see METHODS OF USE (Smoking dried cannabis)
- SOCIAL ADJUSTMENT
- SPINAL CORD INJURY
- STEM CELLS
- SUICIDE DISEASE see TIC DOULOURREUX
- TAXONOMY (Genetics of cannabis)
- TEA AS MEDICINE (Cannabis/ marijuana)
- TETRAHYDROCANNABINOL (THC) annabinoid
- TETRAHYDROCANNABINOLIC ACID (THCA) annabinoid
- TETRAHYDROCANNABOVARIN (THCV) annabinoid
- TIC DOULOURREUX
- TOBACCO VS CANNABIS
- TOURETTE'S SYNDROME
- TRIGEMINAL NEURALGIA
- ULCERATIVE COLITIS see CROHN'S
- URINE (Drug testing)
- VAPORIZERS (also see Methods of use)
- VARIOUS CANCERS (Unknown)
- VISION (Glaucoma)
- WILSON'S DISEASE
- WIN 55,212-2 a synthetic cannabinoid
- WITHDRAWAL SYNDROME
- YOUNG ADULTS see CHILDREN